Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Given Average Rating of "Hold" by Analysts

Adaptimmune Therapeutics PLC (NASDAQ:ADAP - Get Free Report) has received an average recommendation of "Hold" from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $1.35.

ADAP has been the subject of several research reports. Wall Street Zen initiated coverage on shares of Adaptimmune Therapeutics in a research report on Friday, May 16th. They issued a "buy" rating for the company. Mizuho lowered shares of Adaptimmune Therapeutics from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $1.50 to $0.50 in a research report on Thursday, June 26th. Wells Fargo & Company cut their target price on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 14th. Barclays cut their price target on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a research report on Wednesday, May 14th. Finally, Jones Trading lowered shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Long Focus Capital Management LLC raised its stake in Adaptimmune Therapeutics by 15.9% in the first quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company's stock worth $4,680,000 after buying an additional 3,262,294 shares in the last quarter. Two Seas Capital LP raised its stake in Adaptimmune Therapeutics by 38.4% in the first quarter. Two Seas Capital LP now owns 20,529,685 shares of the biotechnology company's stock worth $4,044,000 after buying an additional 5,694,539 shares in the last quarter. Renaissance Technologies LLC raised its stake in Adaptimmune Therapeutics by 52.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after buying an additional 869,949 shares in the last quarter. Rock Springs Capital Management LP increased its stake in shares of Adaptimmune Therapeutics by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after purchasing an additional 58,000 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Adaptimmune Therapeutics by 334.8% during the first quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company's stock valued at $424,000 after purchasing an additional 1,707,999 shares in the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Price Performance

Shares of ADAP traded up $0.01 during mid-day trading on Thursday, reaching $0.35. 1,102,004 shares of the stock traded hands, compared to its average volume of 1,341,757. The firm has a fifty day moving average price of $0.27 and a 200 day moving average price of $0.37. The company has a market cap of $91.95 million, a price-to-earnings ratio of -1.28 and a beta of 2.18. The company has a current ratio of 2.02, a quick ratio of 1.79 and a debt-to-equity ratio of 4.24. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. The firm had revenue of $7.29 million during the quarter, compared to analyst estimates of $6.55 million. As a group, equities research analysts predict that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.